본문으로 건너뛰기
← 뒤로

Up-to-date prevalence at recommended ages for discontinuing routine colorectal, cervical and lung cancer screening.

1/5 보강
Journal of the National Cancer Institute 📖 저널 OA 39.2% 2023: 3/4 OA 2024: 6/8 OA 2025: 30/56 OA 2026: 33/113 OA 2023~2026 2026
Retraction 확인
출처

Pocobelli G, Del Vecchio NJ, Cushing-Haugen K, Kamineni A, Corley DA, Rendle KA, Halm EA, Li CI, Oshiro CES, Carroll NM, Silver MI, Greenlee RT, Neslund-Dudas C, Breslau ES, Chubak J

ℹ️ 이 논문은 무료 전문이 아직 없습니다. 코퍼스 전체의 43.9%는 무료 가능 (통계 →) · 🏥 기관 EZproxy로 시도

📝 환자 설명용 한 줄

Cancer screening guidelines specify ages at which routine screening should be discontinued and, except for cervical cancer screening, do not require specific screening history criteria be met for disc

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • 표본수 (n) 316,756

이 논문을 인용하기

↓ .bib ↓ .ris
APA Pocobelli G, Del Vecchio NJ, et al. (2026). Up-to-date prevalence at recommended ages for discontinuing routine colorectal, cervical and lung cancer screening.. Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djag044
MLA Pocobelli G, et al.. "Up-to-date prevalence at recommended ages for discontinuing routine colorectal, cervical and lung cancer screening.." Journal of the National Cancer Institute, 2026.
PMID 41697970 ↗

Abstract

Cancer screening guidelines specify ages at which routine screening should be discontinued and, except for cervical cancer screening, do not require specific screening history criteria be met for discontinuation. We estimated the prevalence of being up to date with average-risk screening guidelines for colorectal, cervical, and lung cancer as of the recommended ages for discontinuation of routine screening. We conducted a descriptive study among several U.S. healthcare systems during 2010-2019. Up-to-date screening prevalence, based on U.S. Preventive Services Task Force guidelines, was ascertained prior to 76th, 66th, and 81st birthdays among persons eligible for colorectal (N = 316,756 persons), cervical (N = 20,282 persons), and lung cancer (N = 1,151 persons) screening, respectively. Up-to-date screening prevalence was 84.4% for colorectal, 58.9% for cervical, and 6.3% for lung cancer screening. Up-to-date screening prevalence at the ages recommended for discontinuing routine colorectal, cervical, and lung cancer screening varied appreciably, and was particularly low for lung cancer screening.